Boost For Brain Cancer As Tocagen Enters EMA’s PRIME
Brain tumors now equal lymphoma as the most common type of cancers being targeted by oncology products on the European Medicines Agency’s priority medicines (PRIME) scheme for getting medicines for unmet medical needs to patents faster.
You may also be interested in...
The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or meet any secondary endpoints in a Phase III study in recurrent high-grade glioma.
Kite Pharma claims it has filed the first EU application to market a CAR T-cell therapy, and says that being on the European Medicines Agency’s PRIME scheme was helpful when it came to getting answers to the questions it had on the application.
Advice on the acceptability of registry-based studies as a source of evidence for regulatory purposes is included in new guidance from the European Medicines Agency.